Tyra Biosciences, Inc. $TYRA Shares Acquired by HighVista Strategies LLC

HighVista Strategies LLC boosted its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 163.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,812 shares of the company’s stock after purchasing an additional 40,850 shares during the period. HighVista Strategies LLC owned about 0.12% of Tyra Biosciences worth $921,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Millennium Management LLC grew its holdings in Tyra Biosciences by 28.2% in the first quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock valued at $3,759,000 after purchasing an additional 89,024 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Tyra Biosciences by 21.7% in the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock valued at $725,000 after buying an additional 13,896 shares in the last quarter. Woodline Partners LP acquired a new position in shares of Tyra Biosciences during the 1st quarter worth $931,000. Jane Street Group LLC acquired a new position in shares of Tyra Biosciences during the 1st quarter worth $324,000. Finally, Geode Capital Management LLC boosted its position in shares of Tyra Biosciences by 9.8% in the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock worth $5,428,000 after buying an additional 50,836 shares in the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Robert J. More sold 10,000 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the transaction, the director directly owned 3,823,425 shares in the company, valued at approximately $95,585,625. This represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 15.20% of the company’s stock.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $37.01 on Tuesday. The stock has a fifty day moving average of $31.41 and a two-hundred day moving average of $22.27. The company has a market capitalization of $1.99 billion, a PE ratio of -18.41 and a beta of 1.06. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $37.84.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). As a group, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TYRA. Wedbush upped their price target on shares of Tyra Biosciences from $37.00 to $53.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Barclays began coverage on shares of Tyra Biosciences in a research note on Tuesday, January 27th. They set an “overweight” rating for the company. Wall Street Zen downgraded Tyra Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, January 21st. Finally, Piper Sandler raised their price target on Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Tyra Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $42.33.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.